跳至主要内容
临床试验/CTRI/2024/07/071196
CTRI/2024/07/071196尚未招募4 期

Comparison of Effectiveness and Safety of Dapagliflozin and Empagliflozin in Type 2 Diabetes Mellitus - NI

Dr Manu Arya0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • All Patients with Type2 diabetes mellitus as per ADA guidelines
  • Patients of either gender with age more than 18 years.
  • Patients giving written informed consent.

排除标准

  • Pregnant & lactating women.
  • Patients not complying with the study protocol.
  • Patients with underlying comorbid conditions like recurrent UTI, chronic renal diseases.
  • Patients with co-morbid conditions like malignancy, psychiatric disorders, substance abuse
  • Patients with concomitant medications likely to interfere with glycemic control e.g.: Steroids, Beta-blockers, Thiazide Diuretics

研究者

发起方
Dr Manu Arya

相似试验